Studies have shown that patients with breast cancer could develop cardiovascular diseases (CVD) during treatment because of the cardiotoxicity from chemo-or radio-therapy and targeted therapy (e.g., anti-HER2 therapeutics) [3–6], and CVD has become an important factor in all-cause mortality of breast cancer patients [7]. Here, ERBB2 is linked to breast cancer.